基于CT影像基因组学的胰腺神经内分泌肿瘤分子分型和预后预测研究

注册号:

Registration number:

ChiCTR2400092235 

最近更新日期:

Date of Last Refreshed on:

2024-11-12 17:41:31 

注册时间:

Date of Registration:

2024-11-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于CT影像基因组学的胰腺神经内分泌肿瘤分子分型和预后预测研究

Public title:

Molecular typing and prognostic prediction of pancreatic neuroendocrine tumors based on CT imaging genomics

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于CT影像基因组学的胰腺神经内分泌肿瘤分子分型和预后预测研究

Scientific title:

Molecular typing and prognostic prediction of pancreatic neuroendocrine tumors based on CT imaging genomics

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

谭清泉 

研究负责人:

王幸 

Applicant:

Tan Qingquan 

Study leader:

Wang Xing 

申请注册联系人电话:

Applicant telephone:

+86 183 8015 6636

研究负责人电话:

Study leader's
telephone:

+86 183 2873 0806

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

tanqq_dx@163.com

研究负责人电子邮件:

Study leader's E-mail:

wilson_wang@scu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市武侯区国学巷37号

研究负责人通讯地址:

四川省成都市武侯区国学巷37号

Applicant address:

No 37, Guo Xue Alley, Chengdu, Sichuan,China

Study leader's address:

No 37, Guo Xue Alley, Chengdu, Sichuan,China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川大学华西医院

Applicant's institution:

West China Hospital, Sichuan University

研究负责人所在单位:

四川大学华西医院

Affiliation of the Leader:

West China Hospital, Sichuan University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

No.2024(1134)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院生物医学伦理审查委员会

Name of the ethic committee:

Ethics Committee of Sichuan University, West China Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-07-15 00:00:00

伦理委员会联系人:

李娜

Contact Name of the ethic committee:

Li Na

伦理委员会联系地址:

四川省成都市国学巷37号八角亭2105办公室

Contact Address of the ethic committee:

No 37, Guo Xue Alley, Chengdu, Sichuan,China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 8542 2654

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院

Primary sponsor:

West China Hospital, Sichuan University

研究实施负责(组长)单位地址:

四川省成都市武侯区国学巷37号

Primary sponsor's address:

No 37, Guo Xue Alley, Chengdu, Sichuan,China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

Country:

China

Province:

Sichuan

City:

单位(医院):

四川大学华西医院

具体地址:

四川省成都市武侯区国学巷37号

Institution
hospital:

West China Hospital, Sichuan University

Address:

No 37, Guo Xue Alley, Chengdu, Sichuan,China

经费或物资来源:

四川省科技厅重点研发项目

Source(s) of funding:

Sichuan Province Science and Technology Planning Project

研究疾病:

胰腺神经内分泌肿瘤  

Target disease:

pancreatic neuroendocrine neoplasms

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

1.建立胰腺神经内分泌肿瘤(PNENs)的多维度临床病理特征数据库; 2.建立基于术前CT 图像的影像组学图像数据库; 3.建立PNENs转录组、全基因组甲基化测序图谱,结合病理特征及预后建立预后预测模型及分子分型,对相关标志物在血液及组织标本中进行验证; 4.应用多组学数据联合分析,将 CT影像组学标签与测序图谱相关分子分型标志物进行关联分析,解码PNENs精准分型依据;  

Objectives of Study:

1.To establish a multi-dimensional clinicopathological database of pancreatic neuroendocrine neoplasms (PNENs); 2.Establish an image omics image database based on preoperative CT images; 3. PNENs transcriptome and whole genome methylation sequencing map were established, prognosis prediction models and molecular typing were established based on pathological characteristics and prognosis, and related markers were verified in blood and tissue samples; 4.Combined analysis of multi-omics data was used to conduct correlation analysis between CT image omics labels and molecular typing markers related to sequencing maps, and to decode the precise typing basis of PNENs;

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.术中冰冻及术后病理证实为非神经内分泌肿瘤的其它肿瘤如导管腺癌等的病人; 2.未能获得满足测序条件所需的样本; 3.合并其他系统的恶性肿瘤或既往恶性肿瘤病史; 4.存在短期内影响患者生存的其他疾病。

Exclusion criteria:

1.Patients with other tumors, such as ductal adenocarcinoma, which were confirmed by intraoperative freezing and postoperative pathology as non-neuroendocrine tumors; 2. The samples required for sequencing cannot be obtained; 3. Combined with malignant tumors of other systems or a history of previous malignant tumors; 4.There are other diseases that affect the survival of patients in the short term.

研究实施时间:

Study execute time:

From 2024-12-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-12-01 00:00:00 To 2026-12-31 00:00:00

干预措施:

Interventions:

组别:

PNENs组

样本量:

200

Group:

PNENs group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

四川大学华西医院 

单位级别:

三甲 

Institution
hospital:

West China Hospital, Sichuan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

生存时间

指标类型:

主要指标

Outcome:

Survival

Type:

Primary indicator

测量时间点:

术后1,3,5年

测量方法:

电话/门诊随访

Measure time point of outcome:

1,3,5 years after surgery

Measure method:

Telephone/outpatient follow-up

指标中文名:

出生日期

指标类型:

次要指标

Outcome:

Date of Birth

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

身高

指标类型:

次要指标

Outcome:

Height

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体重

指标类型:

次要指标

Outcome:

Body Weight

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

民族

指标类型:

次要指标

Outcome:

Race

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

病史

指标类型:

次要指标

Outcome:

Medical history

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血红蛋白

指标类型:

次要指标

Outcome:

Hemoglobin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血小板计数

指标类型:

次要指标

Outcome:

Platelet count

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白细胞计数

指标类型:

次要指标

Outcome:

White blood cell count

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中性粒细胞计数

指标类型:

次要指标

Outcome:

Neutrophil count

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总胆红素

指标类型:

次要指标

Outcome:

Total bilirubin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

直接胆红素

指标类型:

次要指标

Outcome:

Direct bilirubin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

间接胆红素

指标类型:

次要指标

Outcome:

Indirect bilirubin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

谷丙转氨酶

指标类型:

次要指标

Outcome:

Alanine aminotransferase

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

谷草转氨酶

指标类型:

次要指标

Outcome:

Aspartate transaminase

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白蛋白

指标类型:

次要指标

Outcome:

Albumin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总蛋白

指标类型:

次要指标

Outcome:

Total protein

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血尿素氮

指标类型:

次要指标

Outcome:

Blood urea nitrogen

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肌酐

指标类型:

次要指标

Outcome:

Creatinine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿素

指标类型:

次要指标

Outcome:

Urea

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

葡萄糖

指标类型:

次要指标

Outcome:

Glucose

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脂肪酶

指标类型:

次要指标

Outcome:

Lipase

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

淀粉酶

指标类型:

次要指标

Outcome:

Amylase

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

CA125

指标类型:

次要指标

Outcome:

CA125

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

CA199

指标类型:

次要指标

Outcome:

CA199

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

CEA

指标类型:

次要指标

Outcome:

CEA

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术记录

指标类型:

次要指标

Outcome:

Surgical records

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

围手术期并发症

指标类型:

主要指标

Outcome:

Perioperative complications

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

影像学检查报告及图像

指标类型:

主要指标

Outcome:

Imaging examination report and images

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

胰腺

Sample Name:

Blood

Tissue:

Pancreas

人体标本去向

使用后销毁  

说明

制作蜡块及冻存

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例数据由四川大学华西医院HIS系统导出,并制作CRF表。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case data were exported by HIS system of West China Hospital of Sichuan University, and CRF tables were made.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-11-12 17:41:24